April 15, 2019
Librede Inc. Receives Patent for Tetrahydrocannabinolic acid (THCA) Production in Yeast
Librede hasbeen granted a new patent to produce tetrahydrocannabinolic acid (THCA)in yeast.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 15, 2019
Promethera Biosciences Presents Updated Phase 2a Results for World’s First Stem Cell Clinical Trial in ACLF at The International Liver Congress™/ EASL 2019
Promethera Biosciences’ Interim safety results and early efficacy signals with HepaStem bodewell for subsequent confirmatory trials in ACLF and provide valuableinsights for imminent start of clinical evaluation in NASH
April 15, 2019
New post-hoc analysis of EMPA-REG OUTCOME examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease
Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes…
April 15, 2019
Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens
Shionogi presented data suggest cefiderocol shows a high potential for treating infections caused by themost difficult to treat Gram-negative (GN) bacteria collected fromacross Europe, including multidrug-resistant strains.
April 14, 2019
Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management
United States Foodand Drug Administration (FDA) has cleared the Company’s lead productcandidate, PLENITY (Gelesis100), as an aid in weight management inadults with a Body Mass Index (BMI) of 25–40 kg/m2, when usedin conjunction with diet and exercise.
April 13, 2019
Dr. Reddy’s Laboratories Announces Acquisition of ANDA Portfolio
Dr.Reddy’s has entered into a definitive agreement toacquire a portfolio of 42 approved, non-marketed Abbreviated New DrugApplications (ANDAs) in the U.S.
April 13, 2019
Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019
ASPECT-NP Clinical Trial Results Demonstrated Non-Inferiority of ZERBAXA to Meropenem for Treating Ventilated Nosocomial Pneumonia in Primary and Key Secondary…
April 13, 2019
Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019
ASPECT-NP Clinical Trial Results Demonstrated Non-Inferiority of ZERBAXA to Meropenem for Treating Ventilated Nosocomial Pneumonia in Primary and Key Secondary…
April 13, 2019
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data – – –…
April 12, 2019
QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer
Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ (erdafitinib), developed by Janssen…